RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2

Abstract

All regimens yielded similar acute rejection rates and graft survival, but the tacrolimus + MMF regimen was associated with the lowest rate of steroid resistant rejection requiring antilymphocyte therapy.